Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sibutramine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 known ✓ | Q01959 | 16/20 | 0.94 |
| ▸ | SLC6A4 known ✓ | P31645 | 16/20 | 0.94 |
| ▸ | SLC6A2 known ✓ | P23975 | 9/20 | 0.94 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.97 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.97 |
| ▸ | TSHR | P16473 | 2/20 | 0.97 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.97 |
| ▸ | LMNA | P02545 | 1/20 | 0.97 |
| ▸ | MAPT | P10636 | 1/20 | 0.97 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.97 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.94 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.94 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.94 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.94 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.94 |
| ▸ | HTR2A | P28223 | 1/20 | 0.94 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.94 |
| ▸ | HTR2B | P41595 | 1/20 | 0.94 |
| ▸ | TP53 | P04637 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sibutramine SCHEMBL3855473 | 1.00 | CYP3A4 (0.97) | CYP3A4ALOX15TSHRALDH1A1LMNA | |
| Sibutramine SCHEMBL4594859 | 1.00 | CYP3A4 (0.97) | CYP3A4ALOX15TSHRALDH1A1LMNA | |
| Sibutramine SCHEMBL4051966 | 1.00 | CYP3A4 (0.97) | CYP3A4ALOX15TSHRALDH1A1LMNA | |
| Sibutramine SCHEMBL7191483 | 0.99 | CYP3A4 (1.00) | CYP3A4ALOX15TSHRALDH1A1LMNA | |
| Sibutramine SCHEMBL6431587 | 0.99 | SLC6A3 (0.97) | CYP3A4ALOX15TSHRALDH1A1LMNA | |
| Sibutramine SCHEMBL2916993 | 0.99 | SLC6A3 (0.97) | CYP3A4ALOX15TSHRALDH1A1LMNA | |
| Sibutramine SCHEMBL7189499 | 0.99 | CYP3A4 (1.00) | CYP3A4ALOX15TSHRALDH1A1LMNA | |
| Sibutramine SCHEMBL7626175 | 0.99 | CYP3A4 (1.00) | CYP3A4ALOX15TSHRALDH1A1LMNA | |
| Sibutramine SCHEMBL1598 | 0.99 | CYP3A4 (1.00) | CYP3A4ALOX15TSHRALDH1A1LMNA | |
| Sibutramine SCHEMBL2955 | 0.97 | SLC6A3 (1.00) | CYP3A4ALOX15TSHRALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 4946 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240390364-A1 | Novel Pyridine Compositions and their use in methods for preventing or treating diseases, disorders and conditions | REID CHRISTOPHER BRIAN (US) | 2024-11-28 | — | — | US | claimed |
| US-20230381168-A1 | ADJUNCTIVE THERAPY FOR DEPRESSION | ANEUROTECH BV (BE) | 2023-11-30 | — | — | US | claimed |
| US-11004545-B2 | Clinical effect of pharmaceutical products using communication tool integrated with compound of several pharmaceutical products | INTELLECTUAL PROPERTY ENABLER STOCKHOLM AB (SE) | 2021-05-11 | — | — | US | claimed |
| US-20190127433-A1 | GLUCAGON/GLP-1 RECEPTOR CO-AGONISTS | UNIV INDIANA RES & TECH CORP (US) | 2019-05-02 | — | — | US | claimed |
| US-20190122749-A1 | CLINICAL EFFECT OF PHARMACEUTICAL PRODUCTS USING COMMUNICATION TOOL INTEGRATED WITH COMPOUND OF SEVERAL PHARMACEUTICAL PRODUCTS | INTELLECTUAL PROPERTY ENABLER STOCKHOLM AB (SE) | 2019-04-25 | — | — | US | claimed |
| US-10174093-B2 | Glucagon/GLP-1 receptor co-agonists | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2019-01-08 | — | — | US | claimed |
| WO-2018089773-A1 | SYSTEMS, DEVICES, AND METHODS FOR PERFORMING MEDICAL PROCEDURES IN THE INTESTINE | FRACTYL LABORATORIES, INC. (US) | 2018-05-17 | — | — | WO | claimed |
| US-20170349642-A1 | GLUCAGON/GLP-1 RECEPTOR CO-AGONISTS | UNIV INDIANA RES & TECH CORP (US) | 2017-12-07 | — | — | US | claimed |
| WO-2017161387-A1 | COMPOSITIONS OF NATURAL EXTRACTS AND USE THEREOF IN METHODS FOR PREVENTING OR TREATING DISEASES | REID CHRISTOPHER BRIAN (US) | 2017-09-21 | — | — | WO | claimed |
| US-9758562-B2 | Glucagon/GLP-1 receptor co-agonists | Indiana University and Technology Corporation (US) | 2017-09-12 | — | — | US | claimed |
| EP-0397831-A1 | TREATMENT OF OBESITY. | BOOTS CO PLC (GB) | 1990-11-22 | — | — | EP | claimed |
| EP-0282206-B1 | ARYLCYCLOBUTYLALKYLAMINE-DERIVATIVE FOR THE TREATMENT OF PARKINSON'S DISEASE | The Boots Company PLC (GB) | 1990-11-07 | — | — | EP | claimed |
| WO-1990006110-A1 | TREATMENT OF OBESITY | THE BOOTS COMPANY PLC (GB) | 1990-06-14 | — | — | WO | claimed |
| US-4929629-A | ANTIDEPRESSANTS, N,N-DIMETHYL-1-(1-(4-CHLOROPHENYL) CYCLOBUTYL)-3-METHYLBUTYLAMINE HYDROCHLORIDE | BOOTS COMPANY, PLC (GB) | 1990-05-29 | — | — | US | claimed |
| US-4871774-A | PARKINSON*S DISEASE; PHENYL-CYCLOBUTYL-ALKYLAMINES | THE BOOTS COMPANY PLC (GB) | 1989-10-03 | — | — | US | claimed |
| US-4816488-A | AMINE COMPOUND FOR PARKINSON'S DISEASE | THE BOOTS COMPANY PLC (GB) | 1989-03-28 | — | — | US | claimed |
| EP-0303677-A1 | ARYLCYCLOBUTYL DERIVATIVES FOR TREATMENT OF PARKINSON'S DISEASE | The Boots Company PLC (GB) | 1989-02-22 | — | — | EP | claimed |
| EP-0282206-A1 | Arylcyclobutylalkylamine-derivative for the treatment of Parkinson's disease | The Boots Company PLC (GB) | 1988-09-14 | — | — | EP | claimed |
| WO-1988006444-A1 | ARYLCYCLOBUTYL DERIVATIVES FOR TREATMENT OF PARKINSON'S DISEASE | THE BOOTS COMPANY PLC (GB) | 1988-09-07 | — | — | WO | claimed |
| EP-0230742-A1 | N,N-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine hydrochloride monohydrate and pharmaceutical compositions containing it | The Boots Company PLC (GB) | 1987-08-05 | — | — | EP | claimed |